Harmony Biosciences Holdings (HRMY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.98B
Last updated: Nov 17, 2026 at 11:05 AM ET
Harmony Biosciences Holdings (HRMY) Stock Forecast
Analysts expect Harmony Biosciences Holdings (HRMY) to earn $4.76 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.03B. Of 12 analysts, 8 rate the stock Buy or Strong Buy, 3 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 2.33, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 16.7% |
| Buy | 6 | 50.0% |
| Hold | 3 | 25.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 8.3% |
- Consensus
- Buy
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 27.3% and revenue estimates rise 14.6%.
- Fiscal year ending Dec 31, 2026
- $4.76
- EPS consensus, revenue $1.03B
- Fiscal year ending Dec 31, 2027
- $6.06
- EPS consensus, revenue $1.18B
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $4.76 | $4.40 to $5.12 | 2 | $1.03B | $1.02B to $1.04B | 12 |
| Dec 31, 2027 | $6.06 | $5.17 to $6.96 | 2 | $1.18B | $1.07B to $1.27B | 11 |
Quarterly Estimates
The EPS consensus falls from $1.04 for the quarter ending Dec 31, 2026 to $0.82 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.04 | $0.60 to $1.61 | 14 | $287.49M | $265.93M to $306.60M | 14 |
| Mar 31, 2027 | $0.82 | $0.71 to $0.95 | 4 | $259.29M | $245.80M to $277.60M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 6 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 2 |
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
| Quarter ending Mar 31, 2027 | 2 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 8.8% from $5.22.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $4.76 | $5.22 | $5.22 | $5.22 | $5.22 | -8.8% |
| Fiscal year ending Dec 31, 2027 | $6.06 | $7.00 | $7.00 | $6.69 | $6.69 | -9.3% |
| Quarter ending Mar 31, 2027 | $0.82 | $0.85 | $0.83 | $0.83 | $0.83 | -1.2% |
Frequently Asked Questions About HRMY
What is the HRMY stock forecast?
Consensus analyst estimates put Harmony Biosciences Holdings's EPS at $4.76 for the fiscal year ending Dec 31, 2026, on revenue of $1.03B. The consensus rating from 12 analysts is Buy.
How do analysts rate HRMY stock?
Of 12 analysts covering Harmony Biosciences Holdings, 2 rate it Strong Buy, 6 Buy, 3 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from HRMY next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $4.76, with estimates from $4.40 to $5.12 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $6.06, with estimates from $5.17 to $6.96 from 2 analysts.
What revenue do analysts expect from Harmony Biosciences Holdings next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.03B, with estimates from $1.02B to $1.04B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.18B, with estimates from $1.07B to $1.27B.
How many analysts cover HRMY?
12 analysts rate Harmony Biosciences Holdings stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
HRMY pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts